Cardiovasc Diabetol: Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure

Background: Metformin has been widely used for a long time and is an established basic hypoglycemic drug for the treatment of type 2 diabetes (T2D)
.

A number of observational studies have shown that metformin also has clinical benefits and safety in the treatment of T2D patients with heart failure (HF)

Metformin also has clinical benefits and safety in the treatment of T2D patients with heart failure (HF).

Results: In the CANDLE trial, almost all patients had stable clinical performance (New York Heart Association Grade I-II), and approximately 70% of participants did not achieve the ejection fraction for heart failure (defined as left ventricular ejection) at baseline.
Blood score ≥50%)
.

Among 233 patients who were randomized to receive canagliflozin (100 mg/d) or glimepiride (0.

Table NT-proBNP concentration changes from baseline to week 24

Table NT-proBNP concentration changes from baseline to week 24

Figure 1 Changes in NT-proBNP concentration from baseline to week 24 in subgroups stratified by the use of hypoglycemic agents based on baseline
.

A.

Figure 1 Changes in NT-proBNP concentration from baseline to week 24 in subgroups stratified by the use of hypoglycemic agents based on baseline

Figure 2 Changes in systolic blood pressure, BMI, and ePV in subgroups stratified according to baseline hypoglycemic drug use from baseline to 24 weeks
.

A The difference between groups (canagliflozin-glimepiride) from baseline to 24 weeks (*refers to the naïve subgroup)

Figure 2 Changes in systolic blood pressure, BMI, and ePV in subgroups stratified according to baseline hypoglycemic drug use from baseline to 24 weeks

Figure 3 In the subgroups stratified by baseline use of hypoglycemic agents, the change in NYHA classification from baseline at week 24
.

All p values ​​are used for comparison between treatment groups

Figure 3 In the subgroups stratified by baseline use of hypoglycemic agents, the change in NYHA classification from baseline at week 24

The effect of canagliflozin treatment on the concentration of NT-proBNP does not seem to be related to the background medication of diabetes treatment

Tanaka A, Toyoda S, Imai T,et al.

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Leave a message here